Portal de investigación
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Carmona-Bayonas A
- Jiménez-Fonseca P
- Lamarca Á
- Barriuso J
- Castaño Á
- Benavent M
- Alonso V
- Riesco-Martínez MDC
- Alonso-Gordoa T
- Custodio A
- Sánchez Cánovas M
- Hernando Cubero J
- Lacasta A
- Fernández Montes A
- Marazuela M
- Crespo G
- Escudero P
- Diaz JÁ
- Feliciangeli E
- Llanos M
- Vilardell F
- Percovich JC
- Grande E
- Capdevila J
- Valle JW
- García-Carbonero R
Grupos
Abstract
Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients.
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Article
- Páginas:
- 2571-2580
- DOI:
- 10.1200/JCO.19.00980
- PubMed:
- 31390276
- Factor de Impacto:
- 10,054 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS
Citas Recibidas en Web of Science: 64
Documentos
- No hay documentos
Filiaciones
Campos de Estudio
Cita
Carmona A,Jiménez P,Lamarca Á,Barriuso J,Castaño Á,Benavent M,Alonso V,Riesco MDC,Alonso T,Custodio A,Sánchez M,Hernando J,LÓPEZ C,Lacasta A,Fernández A,Marazuela M,Crespo G,Escudero P,Diaz JÁ,Feliciangeli E,GALLEGO J,Llanos M,SEGURA Á,Vilardell F,Percovich JC,Grande E,Capdevila J,Valle JW,García R. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. J. Clin. Oncol. 2019. 37. (28):p. 2571-2580. IF:32,956. (1).